Hepatic Encephalopathy

Definition And Classification

• Metabolically induced, potentially reversible functional disturbance of brain.
• Principal manifestation of acute liver failure and chronic liver disease.
• Type A: Occurs in acute liver failure.
• Type B: Occurs in portosystemic shunting without intrinsic hepatocellular disease.
• Type C: Occurs in chronic liver disease.
• Subclassifications of Type C: Minimal, episodic, or persistent.
• Minimal Hepatic Encephalopathy (Covert HE): Subclinical manifestation detectable exclusively via psychometric tests or electrophysiological techniques. Compromises attention, processing speed, and psychomotor performance.

Pathophysiology

Ammonia Hypothesis

• Ammonia produced primarily in large intestine via bacterial protein breakdown, muscle, and kidney.
• Healthy liver converts ammonia to urea or glutamine.
• Failing liver permits systemic ammonia accumulation; ammonia crosses blood-brain barrier.
• Glial cells convert excess ammonia to glutamine.
• Intracellular glutamine accumulation increases osmotic pressure.
• Results in astrocyte swelling and profound cerebral edema.
• Glutamine competitively inhibits glutamate receptors.
• Induces oxidative stress triggering mitochondrial dysfunction.

Neurotoxins And Altered Neurotransmitters

• Decreased Fischer ratio (branched-chain amino acids to aromatic amino acids).
• Aromatic amino acids (phenylalanine, tyrosine, tryptophan) cross blood-brain barrier.
• Promotes synthesis of false neurotransmitters (octopamine, synephrine).
• Short-chain fatty acids (propionate, butyrate) competitively inhibit urea cycle enzymes.
• Elevated gamma-aminobutyric acid, serotonin, and endogenous benzodiazepine-like compounds alter neurotransmission.

Precipitating Factors

• Gastrointestinal hemorrhage.
• Systemic infection.
• Use of sedatives.
• Dehydration secondary to aggressive diuresis.
• Constipation.
• Electrolyte imbalance (hypokalemia, hyponatremia, alkalosis).
• High dietary protein intake.

Clinical Manifestations And Grading

Clinical Features

• Minor disturbances of consciousness or motor function initially.
• Infants exhibit irritability, poor feeding, inverted sleep rhythm.
• Older children exhibit asterixis (flapping tremor), hypertonia, and hyperreflexia.
• Progression yields hypotonia, areflexia, and coma.
• Parkinsonian features (muscular rigidity, bradykinesia, hypokinesia, monotony of speech, resting tremors) possible.

West Haven Criteria For Grading

Grade	Clinical Signs	Neurologic/Reflex Findings	Electroencephalogram Changes
0	Normal behavior.	Normal.	Normal alpha rhythm.
1	Euphoria/anxiety, shortened attention span, trivial lack of awareness, inverted sleep pattern.	Normal or hyperreflexia.	Appearance of theta rhythm.
2	Subtle personality change, minimal time/place disorientation, lethargy, inappropriate behavior.	Tremor, apraxia, dysarthria, ataxia, hyperreflexia.	Continuous theta rhythm, occasional delta waves.
3	Somnolence to semi-stupor, gross disorientation, combativeness, confusion.	Brisk reflexes, Babinski sign, muscle rigidity.	Prevalent theta rhythm, polyphasic spikes.
4	Deep coma (unresponsive to verbal or noxious stimuli).	Absent reflexes, decerebrate/decorticate posturing.	Continuous delta waves.

Diagnostic Evaluation

Clinical And Neuropsychological Assessment

• Diagnosis relies primarily on clinical history and examination.
• Utilize Wechsler intelligence tests or Dutch child intelligence test for neuropsychological assessment.
• Psychometric hepatic encephalopathy score lacks validation in children.

Electrophysiological And Imaging Modalities

• Critical Flicker Frequency: Quantifies low-grade encephalopathy in children >8 years. Patients perceive flicker only below 39 Hz threshold.
• Electroencephalogram: Grades severity (0-4) based on background rhythm slowing and presence of delta/theta waves.
• Neuroimaging: Computed tomography excludes organic causes (intracranial hemorrhage, tumors). Magnetic resonance imaging detects cerebral edema and demyelination. Proton magnetic resonance spectroscopy measures elevated brain glutamine and depleted myo-inositol/choline.

Management Strategies

General Resuscitation And Monitoring

• Stabilize patient; actively identify and reverse precipitating factors.
• Elective intubation indicated for grade 3 or 4 encephalopathy for airway protection and facilitating hyperventilation.
• Optimize intravascular hydration; monitor central venous pressure (target 6-8 cm H2O).
• Avoid rapid fluid boluses; exacerbates cerebral edema.
• Avoid sedatives; prefer opiates over benzodiazepines if sedation mandated for mechanical ventilation.

Nutritional Therapy

• Maintain adequate caloric intake.
• Restrict protein (1 g/kg) only initially (first 24-48 hours) or in intractable encephalopathy.
• Prolonged protein restriction contraindicated; worsens catabolism and depletes muscle mass.
• Muscle acts as critical ammonia buffer; muscle loss exacerbates hyperammonemia.
• Prefer plant protein and branched-chain amino acids over animal protein and aromatic amino acids.

Ammonia-Lowering Pharmacotherapy

• Lactulose: Decreases colonic pH to ~5, reducing bacterial fermentation. Converts ammonia to non-diffusible ammonium ion for fecal excretion. Titrate dosage to achieve three soft stools daily.
• Lactitol: Non-absorbable sugar alternative; more palatable than lactulose.
• Antibiotics: Rifaximin offers safe oral bowel decontamination; superior safety profile compared to neomycin (neomycin associated with nephrotoxicity and ototoxicity).
• L-ornithine-L-aspartate: Enhances transaminase activity converting ammonia to non-toxic glutamate. Maximum infusion rate 5 g/h (up to 20 g/day); not recommended for children <8 years.
• Ammonia Scavengers: Sodium benzoate and sodium phenylacetate eliminate ammonia via alternate pathways (excreted renally as hippuric acid and phenylacetyl-glutamine).

Cerebral Edema Management

• Administer mannitol (0.5 g/kg 20% solution bolus over 15 minutes). Repeat if serum osmolarity <320 mOsm/L.
• Induce mild cerebral hypothermia (32-35°C).
• Maintain hypernatremia (serum sodium >145 mmol/L) to prevent fluid shifts.
• Maintain cerebral perfusion pressure >50 mm Hg utilizing inotropic agents (noradrenaline preferred).
• Consider continuous kidney replacement therapy for hyperammonemia >150-200 µmol/L with grade III-IV encephalopathy.

Definitive Therapy

• Liver transplantation remains sole definitive treatment for reversing chronic hepatic encephalopathy and end-stage liver disease.